Journey Medical Price To Book vs. Net Income
| DERM Stock | USD 8.15 0.13 1.62% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.72 |
|
|
The module aggregates profitability drivers for Journey Medical with ratios tied to revenue, assets, and equity.
Segment Revenue Breakdown - Journey Medical
Investing Opportunities.
Macro event markers
Journey Medical Revenue by Earnings Segment View
The estimates help frame performance context across reporting periods. This view provides informational context for Journey Medical earnings expectations over time.
Earnings Share -0.35 | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Understanding Journey Medical Corp includes distinguishing between market value and book value, where book value reflects Journey accounting equity. Journey Medical's market capitalization is 266.72 M. With a P/B ratio of 9.93, the market values Journey Medical well above its book equity. Enterprise value stands at 257.59 M. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Journey Medical differs from its quoted price, since each reflects a different lens. For Journey Medical, key inputs include a P/B ratio of 9.93, a profit margin of -14.58%, ROE of -47.05%, and revenue of 56.13 M. Trading price represents the transaction level agreed by market participants.
Journey Medical Corp Net Income vs. Price To Book Fundamental Analysis
Comparative valuation applies peer-based financial ratios to assess Journey Medical's relative market value. Journey Medical Corp currently holds the # 5 position in price to book category among its top compatitors. It currently holds the # 4 position in net income category among its top compatitors . Comparative financial data indicate that Net Loss is shifting by roughly 4.76%. Previously, Net Loss was valued at -16.87 Million. Relative ratio analysis evaluates Journey Medical's earnings valuation.Journey Net Income vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Journey Medical |
| = | 9.93 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Journey Medical |
| = | -14.67 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Journey Net Income Comparison
Journey Medical is currently under evaluation. in net income category among its top compatitors.
Journey Medical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Journey Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Journey Medical will eventually generate negative long term returns. The profitability progress is the general direction of Journey Medical's change in net profit over the period of time. It can combine multiple indicators of Journey Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -15.7 M | -16.5 M | |
| Income Before Tax | -16.8 M | -17.6 M | |
| Total Other Income Expense Net | -840.6 K | -882.6 K | |
| Net Loss | -16.9 M | -17.7 M | |
| Income Tax Expense | 54.9 K | 52.2 K | |
| Net Interest Income | -1.7 M | -1.8 M | |
| Net Loss | -13.2 M | -13.9 M | |
| Net Loss | -26.7 M | -25.3 M | |
| Interest Income | 870.5 K | 914.1 K | |
| Change To Netincome | 25.3 M | 26.5 M | |
| Net Loss | -0.65 | -0.68 | |
| Income Quality | 0.72 | 0.69 | |
| Net Income Per E B T | 0.90 | 0.76 |
Journey Profitability Driver Comparison
Understanding Journey Medical's profitability drivers is a critical part of evaluating Journey Medical as an investment. Unexpected events - from regulatory changes to commodity price movements - can materially alter the profit trajectory and investment outlook during any given holding period.
Journey Medical Earnings Estimation Breakdown
Based on trailing twelve-month earnings reporting, analysts project Journey Medical's next EPS at 0.063125. The range of analyst estimates extends from 0.0425 on the low end to 0.09 on the high end for Journey Medical Corp. Non-recurring items are excluded from this projection to ensure that the estimate reflects sustainable earnings capacity.Last Reported EPS
0.04 Lowest | Expected EPS | 0.09 Highest |
Journey Medical Earnings Projection Consensus
A consensus EPS-based fair value estimate above Journey Medical's current market price may suggest the stock is trading below intrinsic value by some metrics. An estimate below market price raises questions about whether the current valuation is sustainable without stronger earnings growth. Both interpretations are scenario-based and should be paired with fundamental due diligence and risk assessment before allocation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 55.39% | 0.0 | 0.063125 | -0.35 |
Journey Medical Earnings History
Professional analysts covering Journey Medical revise EPS estimates throughout the quarter based on new data, guidance updates, and sector shifts. The final consensus ahead of the earnings date becomes the reference point against which reported results are judged. Comparing consensus trends to actual outcomes over multiple quarters reveals analytical reliability over time.Journey Medical Quarterly Gross Profit | 11.88 Million |
Experienced Journey Medical's investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
Earnings per Share Projection vs Actual
The distinction between actual and expected EPS for Journey Medical is foundational to earnings analysis. Actual EPS is confirmed at the close of each reporting cycle; expected EPS is the analyst consensus formed before reporting. Higher EPS is generally associated with stronger profitability, and the weighted average methodology ensures fairness when share counts fluctuate.Journey Medical Estimated Months Earnings per Share
Income-focused investors in Journey Medical use EPS trends as a proxy for dividend sustainability and future payout growth. Rising EPS supports the ability to maintain or increase distributions; declining EPS may signal payout risk. For best results, EPS should be evaluated alongside payout ratio, free cash flow, and peer comparisons.Journey Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises represent the gap between what Journey Medical reports and what the analyst community projected - a gap that markets price rapidly and often decisively. Both the direction and magnitude of the surprise influence the near-term trend after results are published. Analyst EPS estimates are built from guidance, sector trends, and detailed financial models updated throughout the quarter.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-12 | 2025-09-30 | -0.03 | -0.09 | -0.06 | 200 | ||
2025-08-12 | 2025-06-30 | -0.11 | -0.16 | -0.05 | 45 | ||
2025-06-25 | 2025-03-31 | -0.2375 | -0.18 | 0.0575 | 24 | ||
2025-03-26 | 2024-12-31 | -0.1725 | 0.1 | 0.2725 | 157 | ||
2024-11-12 | 2024-09-30 | -0.17 | -0.12 | 0.05 | 29 | ||
2024-08-06 | 2024-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-05-13 | 2024-03-31 | -0.23 | -0.53 | -0.3 | 130 | ||
2024-03-21 | 2023-12-31 | -0.08 | -0.12 | -0.04 | 50 | ||
2023-11-07 | 2023-09-30 | -0.15 | 0.8 | 0.95 | 633 | ||
2023-08-08 | 2023-06-30 | -0.33 | -0.29 | 0.04 | 12 | ||
2023-05-22 | 2023-03-31 | -0.45 | -0.57 | -0.12 | 26 | ||
2023-03-29 | 2022-12-31 | -0.47 | -0.6 | -0.13 | 27 | ||
2022-11-10 | 2022-09-30 | -0.4 | -0.57 | -0.17 | 42 | ||
2022-08-09 | 2022-06-30 | -0.26 | -0.43 | -0.17 | 65 | ||
2022-05-10 | 2022-03-31 | -0.31 | -0.08 | 0.23 | 74 | ||
2022-03-23 | 2021-12-31 | -0.41 | -1.64 | -1.23 | 300 | ||
2021-12-10 | 2021-09-30 | -0.87 | 0.32 | 1.19 | 136 | ||
2021-09-01 | 2021-06-30 | -1.3 | -0.72 | 0.58 | 44 | ||
2019-11-05 | 2019-09-30 | -1.3 | -1.06 | 0.24 | 18 | ||
2019-08-07 | 2019-06-30 | -0.95 | -0.33 | 0.62 | 65 | ||
2019-05-07 | 2019-03-31 | -1.62 | -1.49 | 0.13 | 8 | ||
2019-02-26 | 2018-12-31 | -1.91 | -1.7 | 0.21 | 10 | ||
2018-11-07 | 2018-09-30 | -1.63 | -1.58 | 0.05 | 3 | ||
2018-08-06 | 2018-06-30 | -0.51 | -0.57 | -0.06 | 11 | ||
2018-05-03 | 2018-03-31 | -1.36 | -1.42 | -0.06 | 4 | ||
2018-02-22 | 2017-12-31 | -1.22 | -1.34 | -0.12 | 9 | ||
2017-11-06 | 2017-09-30 | -1.12 | -4.3 | -3.18 | 283 | ||
2017-08-07 | 2017-06-30 | -0.89 | -0.93 | -0.04 | 4 | ||
2017-05-08 | 2017-03-31 | -0.89 | -0.79 | 0.1 | 11 | ||
2017-02-28 | 2016-12-31 | -0.8 | -0.21 | 0.59 | 73 | ||
2016-11-07 | 2016-09-30 | -0.72 | -0.72 | 0.0 | 0 | ||
2016-08-08 | 2016-06-30 | -0.86 | -0.89 | -0.03 | 3 | ||
2016-05-10 | 2016-03-31 | -0.94 | -0.95 | -0.01 | 1 | ||
2016-03-03 | 2015-12-31 | -0.95 | -1.04 | -0.09 | 9 | ||
2015-11-10 | 2015-09-30 | -0.77 | -0.58 | 0.19 | 24 | ||
2015-08-13 | 2015-06-30 | -0.75 | -0.69 | 0.06 | 8 | ||
2015-05-12 | 2015-03-31 | -0.65 | -0.57 | 0.08 | 12 | ||
2015-03-25 | 2014-12-31 | -0.6 | -0.29 | 0.31 | 51 | ||
2014-11-12 | 2014-09-30 | -0.93 | -8.67 | -7.74 | 832 |
Use Journey Medical in pair-trading
Pair trading with Journey Medical can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Journey Medical Pair Trading
Journey Medical Corp Pair Trading Analysis
Identifying correlated replacements for Journey Medical is particularly important in concentrated portfolios where Journey Medical Corp represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Journey Medical it is a practical tool. High correlations between Journey Medical Corp and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Journey Medical can support hedging context. The method can be applied across sectors and broader equity sets.Use Investing Themes to Complement your Journey Medical position
Using Journey Medical Corp inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Journey Stock Analysis
Reviewing Journey Medical Corp commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Journey Stock:Investing Opportunities. Analysis related to Journey Medical should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
A projection view for Journey Medical Corp starts with historical financial statements. The core view includes income statement, balance sheet, and cash flow.